|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PQBP1 |
Gene summary for PQBP1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PQBP1 | Gene ID | 10084 |
| Gene name | polyglutamine binding protein 1 | |
| Gene Alias | MRX2 | |
| Cytomap | Xp11.23 | |
| Gene Type | protein-coding | GO ID | GO:0000375 | UniProtAcc | A0A0S2Z4V5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10084 | PQBP1 | LZE4T | Human | Esophagus | ESCC | 1.56e-14 | 5.58e-01 | 0.0811 |
| 10084 | PQBP1 | LZE7T | Human | Esophagus | ESCC | 3.01e-10 | 5.38e-01 | 0.0667 |
| 10084 | PQBP1 | LZE8T | Human | Esophagus | ESCC | 2.87e-07 | 1.40e-01 | 0.067 |
| 10084 | PQBP1 | LZE20T | Human | Esophagus | ESCC | 9.89e-06 | 3.49e-01 | 0.0662 |
| 10084 | PQBP1 | LZE22D1 | Human | Esophagus | HGIN | 3.31e-02 | -8.38e-02 | 0.0595 |
| 10084 | PQBP1 | LZE22T | Human | Esophagus | ESCC | 2.84e-04 | 1.56e-01 | 0.068 |
| 10084 | PQBP1 | LZE24T | Human | Esophagus | ESCC | 3.39e-15 | 4.19e-01 | 0.0596 |
| 10084 | PQBP1 | LZE21T | Human | Esophagus | ESCC | 1.47e-08 | 3.19e-01 | 0.0655 |
| 10084 | PQBP1 | LZE6T | Human | Esophagus | ESCC | 2.30e-09 | 1.80e-01 | 0.0845 |
| 10084 | PQBP1 | P1T-E | Human | Esophagus | ESCC | 2.11e-12 | 6.60e-01 | 0.0875 |
| 10084 | PQBP1 | P2T-E | Human | Esophagus | ESCC | 1.17e-40 | 9.57e-01 | 0.1177 |
| 10084 | PQBP1 | P4T-E | Human | Esophagus | ESCC | 5.24e-34 | 8.72e-01 | 0.1323 |
| 10084 | PQBP1 | P5T-E | Human | Esophagus | ESCC | 4.36e-32 | 5.80e-01 | 0.1327 |
| 10084 | PQBP1 | P8T-E | Human | Esophagus | ESCC | 1.02e-45 | 9.03e-01 | 0.0889 |
| 10084 | PQBP1 | P9T-E | Human | Esophagus | ESCC | 4.21e-29 | 7.52e-01 | 0.1131 |
| 10084 | PQBP1 | P10T-E | Human | Esophagus | ESCC | 1.44e-22 | 4.34e-01 | 0.116 |
| 10084 | PQBP1 | P11T-E | Human | Esophagus | ESCC | 4.05e-13 | 8.39e-01 | 0.1426 |
| 10084 | PQBP1 | P12T-E | Human | Esophagus | ESCC | 5.19e-26 | 5.96e-01 | 0.1122 |
| 10084 | PQBP1 | P15T-E | Human | Esophagus | ESCC | 6.45e-37 | 8.44e-01 | 0.1149 |
| 10084 | PQBP1 | P16T-E | Human | Esophagus | ESCC | 7.03e-38 | 7.82e-01 | 0.1153 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000838026 | Esophagus | HGIN | RNA splicing | 160/2587 | 434/18723 | 3.74e-34 | 1.12e-30 | 160 |
| GO:000037520 | Esophagus | HGIN | RNA splicing, via transesterification reactions | 115/2587 | 324/18723 | 3.16e-23 | 3.80e-20 | 115 |
| GO:000037720 | Esophagus | HGIN | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 113/2587 | 320/18723 | 1.24e-22 | 9.26e-20 | 113 |
| GO:000039820 | Esophagus | HGIN | mRNA splicing, via spliceosome | 113/2587 | 320/18723 | 1.24e-22 | 9.26e-20 | 113 |
| GO:004348427 | Esophagus | HGIN | regulation of RNA splicing | 59/2587 | 148/18723 | 3.61e-15 | 7.22e-13 | 59 |
| GO:000038018 | Esophagus | HGIN | alternative mRNA splicing, via spliceosome | 32/2587 | 77/18723 | 2.06e-09 | 1.54e-07 | 32 |
| GO:00324817 | Esophagus | HGIN | positive regulation of type I interferon production | 16/2587 | 58/18723 | 4.35e-03 | 3.84e-02 | 16 |
| GO:000961517 | Esophagus | HGIN | response to virus | 69/2587 | 367/18723 | 4.39e-03 | 3.86e-02 | 69 |
| GO:00324794 | Esophagus | HGIN | regulation of type I interferon production | 23/2587 | 95/18723 | 4.51e-03 | 3.93e-02 | 23 |
| GO:00326064 | Esophagus | HGIN | type I interferon production | 23/2587 | 95/18723 | 4.51e-03 | 3.93e-02 | 23 |
| GO:0008380111 | Esophagus | ESCC | RNA splicing | 336/8552 | 434/18723 | 1.74e-42 | 3.67e-39 | 336 |
| GO:0000375111 | Esophagus | ESCC | RNA splicing, via transesterification reactions | 248/8552 | 324/18723 | 3.05e-30 | 1.49e-27 | 248 |
| GO:0000377111 | Esophagus | ESCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 244/8552 | 320/18723 | 2.52e-29 | 1.07e-26 | 244 |
| GO:0000398111 | Esophagus | ESCC | mRNA splicing, via spliceosome | 244/8552 | 320/18723 | 2.52e-29 | 1.07e-26 | 244 |
| GO:0043484111 | Esophagus | ESCC | regulation of RNA splicing | 116/8552 | 148/18723 | 3.18e-16 | 2.38e-14 | 116 |
| GO:000961518 | Esophagus | ESCC | response to virus | 238/8552 | 367/18723 | 6.65e-14 | 3.32e-12 | 238 |
| GO:00516075 | Esophagus | ESCC | defense response to virus | 171/8552 | 265/18723 | 3.91e-10 | 1.05e-08 | 171 |
| GO:01405465 | Esophagus | ESCC | defense response to symbiont | 171/8552 | 265/18723 | 3.91e-10 | 1.05e-08 | 171 |
| GO:00028318 | Esophagus | ESCC | regulation of response to biotic stimulus | 191/8552 | 327/18723 | 2.12e-06 | 2.45e-05 | 191 |
| GO:000038019 | Esophagus | ESCC | alternative mRNA splicing, via spliceosome | 55/8552 | 77/18723 | 4.07e-06 | 4.38e-05 | 55 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0304018 | Esophagus | HGIN | Spliceosome | 79/1383 | 217/8465 | 3.22e-13 | 7.00e-12 | 5.56e-12 | 79 |
| hsa0304019 | Esophagus | HGIN | Spliceosome | 79/1383 | 217/8465 | 3.22e-13 | 7.00e-12 | 5.56e-12 | 79 |
| hsa0304027 | Esophagus | ESCC | Spliceosome | 128/4205 | 217/8465 | 3.31e-03 | 8.79e-03 | 4.50e-03 | 128 |
| hsa0304037 | Esophagus | ESCC | Spliceosome | 128/4205 | 217/8465 | 3.31e-03 | 8.79e-03 | 4.50e-03 | 128 |
| hsa030407 | Liver | Cirrhotic | Spliceosome | 102/2530 | 217/8465 | 5.69e-08 | 9.47e-07 | 5.84e-07 | 102 |
| hsa0304012 | Liver | Cirrhotic | Spliceosome | 102/2530 | 217/8465 | 5.69e-08 | 9.47e-07 | 5.84e-07 | 102 |
| hsa0304022 | Liver | HCC | Spliceosome | 122/4020 | 217/8465 | 5.55e-03 | 1.60e-02 | 8.91e-03 | 122 |
| hsa0304032 | Liver | HCC | Spliceosome | 122/4020 | 217/8465 | 5.55e-03 | 1.60e-02 | 8.91e-03 | 122 |
| hsa0304016 | Oral cavity | OSCC | Spliceosome | 123/3704 | 217/8465 | 7.21e-05 | 2.74e-04 | 1.40e-04 | 123 |
| hsa0304017 | Oral cavity | OSCC | Spliceosome | 123/3704 | 217/8465 | 7.21e-05 | 2.74e-04 | 1.40e-04 | 123 |
| hsa0304026 | Oral cavity | LP | Spliceosome | 106/2418 | 217/8465 | 1.30e-10 | 2.40e-09 | 1.55e-09 | 106 |
| hsa0304036 | Oral cavity | LP | Spliceosome | 106/2418 | 217/8465 | 1.30e-10 | 2.40e-09 | 1.55e-09 | 106 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PQBP1 | SNV | Missense_Mutation | novel | c.755T>C | p.Leu252Pro | p.L252P | O60828 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PQBP1 | SNV | Missense_Mutation | novel | c.547G>A | p.Glu183Lys | p.E183K | O60828 | protein_coding | deleterious(0.01) | benign(0.091) | TCGA-B6-A0RL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| PQBP1 | SNV | Missense_Mutation | novel | c.125N>T | p.Ala42Val | p.A42V | O60828 | protein_coding | tolerated(0.11) | probably_damaging(0.978) | TCGA-BH-A0H9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| PQBP1 | SNV | Missense_Mutation | c.415G>A | p.Asp139Asn | p.D139N | O60828 | protein_coding | tolerated(0.26) | possibly_damaging(0.453) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD | |
| PQBP1 | SNV | Missense_Mutation | rs782092434 | c.647N>T | p.Thr216Met | p.T216M | O60828 | protein_coding | deleterious(0.01) | possibly_damaging(0.828) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| PQBP1 | SNV | Missense_Mutation | c.79N>C | p.Glu27Gln | p.E27Q | O60828 | protein_coding | deleterious(0) | probably_damaging(0.979) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| PQBP1 | SNV | Missense_Mutation | novel | c.676G>A | p.Glu226Lys | p.E226K | O60828 | protein_coding | deleterious(0.02) | probably_damaging(0.98) | TCGA-ZJ-AAXA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| PQBP1 | SNV | Missense_Mutation | c.270N>T | p.Lys90Asn | p.K90N | O60828 | protein_coding | tolerated(0.06) | probably_damaging(0.987) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| PQBP1 | SNV | Missense_Mutation | novel | c.239N>C | p.Asp80Ala | p.D80A | O60828 | protein_coding | deleterious(0.02) | probably_damaging(0.991) | TCGA-AA-A01D-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | capecitabine | PD |
| PQBP1 | SNV | Missense_Mutation | rs782634968 | c.529C>T | p.Arg177Cys | p.R177C | O60828 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-F4-6570-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |